Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06203002 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
A Phase 2 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 496
- Enrollment target
NCT06203002: Completed Phase 2 study, sponsored by Lexicon Pharmaceuticals.
NCT06203002 is a Phase 2 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 496 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (273% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06203002, a Phase 2 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 496 participants
- Enrollment target
Study Summary
Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP. Please see study website: https://diabeticpainstudy.com/
Primary Outcome
ADPS is based on the 11-point numerical rating scale (NRS) \[0 (no pain) to 10 (worst imaginable pain)\].
Interventions
- DRUG Placebo (blinded)
- DRUG LX9211 (blinded)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2023-11-29 |
| Est. Completion | 2025-02-24 |
| Phase | Phase 2 |
What the finished NCT06203002 record still lists
NCT06203002 is an interventional study that assigns participants to a tested intervention. The registered 496 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (273% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo (blinded) is the first listed.
NCT06203002 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06203002 about?
NCT06203002 is a clinical study titled "A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)". Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP. Please see study website: https://diabeticpainstudy.com/
What is the current status of trial NCT06203002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 496 participants. The study started on 2023-11-29. Estimated completion is 2025-02-24.
What interventions are being tested in trial NCT06203002?
The interventions under investigation include: Placebo (blinded) (DRUG), LX9211 (blinded) (DRUG).
Who is sponsoring clinical trial NCT06203002?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06203002's enrollment target sits among peer trials
496 75th of 2000 higher than 1,925 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- NCT06778447 · 496 participants · NA
Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI